Abstract
Antiplatelet agents, including aspirin and clopidogrel, remain the primary therapeutic options for secondary prevention of ischaemic non‐embolic stroke. The effectiveness of the applied therapy and the appropriate choice of agent is of key importance to subjects after stroke, contributing to minimising the risk of recurrent vascular events. However, the efficacy of antiplatelet agents is variable and in many cases definitely insufficient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
